Genistein crystalline - Axcentua

Drug Profile

Genistein crystalline - Axcentua

Alternative Names: AXP-107 11; genistein sodium salt dihydrate; genistein-SSDH

Latest Information Update: 25 Sep 2015

Price : $50

At a glance

  • Originator Axcentua Pharmaceuticals
  • Class Antineoplastics; Chemosensitisers; Isoflavones; Osteoporosis therapies; Phytotherapies; Small molecules
  • Mechanism of Action Apoptosis stimulants; DNA topoisomerase inhibitors; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis III
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Pancreatic cancer
  • Preclinical Mucopolysaccharidosis III; Solid tumours

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 25 Sep 2015 Phase-I/II development for Pancreatic cancer is ongoing in Sweden
  • 02 Apr 2014 Preclinical trials in Mucopolysaccharidosis III in Sweden (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top